A pilot programme of hepatitis B vaccination was set up in three prisons to assess the feasibility and results of this method of reaching a high-risk population. hepatitis B vaccine was offered to all inmates who lacked serological markers for hepatitis B virus.
The antibody response was assessed in those who received two or three doses of vaccine.
Candidates for vaccination were 41% of 1755 imprisoned men (20% of intravenous drug users (IVDU) and 63% of non-IVDU), but complete vaccination could be given to only 33% of candidates.
A further 29% received two doses.
Seroconversion to anti-HBs (titres >10 IU l-1) occurred in 33% of vaccinees after two doses and in 76% after three doses.
Mots-clés Pascal : Virus hépatite B, Hepadnaviridae, Virus, Vaccination, Immunoprotection, Immunogénicité, Milieu carcéral, Homme, Prévention, Espagne, Europe, Hépatite virale B, Virose, Infection, Appareil digestif pathologie, Foie pathologie
Mots-clés Pascal anglais : Hepatitis B virus, Hepadnaviridae, Virus, Vaccination, Immunoprotection, Immunogenicity, Carceral environment, Human, Prevention, Spain, Europe, Viral hepatitis B, Viral disease, Infection, Digestive diseases, Hepatic disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0094633
Code Inist : 002B05C02G. Création : 199406.